Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.


home / news releases / MOR - Morphosys' lead drug successful in mid-stage DLBCL study

MOR - Morphosys' lead drug successful in mid-stage DLBCL study

MorphoSys AG
  • Morphosys AG (NASDAQ:MOR) announces the successful outcome of a Phase 2 clinical trial, L-MIND, evaluating lead candidate MOR208, combined with Celgene's (NASDAQ:CELG) Revlimid (lenalidomide), in patients with relapsed or refractory diffuse large B cell lymphoma (DLBCL) who are ineligible for high-dose chemotherapy and autologous stem cell transplantation.
  • More news on: MorphoSys AG, Celgene Corporation, Healthcare stocks news,
    • Read more ...
Stock Information
Company Name: MorphoSys AG
Stock Symbol: MOR
Market: NASDAQ
Website: morphosys.com
Menu
MOR MOR Quote MOR Short MOR News MOR Articles MOR Message Board
Get MOR Alerts

News, Short Squeeze, Breakout and More Instantly...